Physician profile
Gary Vicik
NPI 1295708212
$10,290.41
in general payments reported to CMS, 2019-2025
25 companies · $755 in 2025
The $755 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,343 · 2020: $1,112 · 2021: $1,130 · 2022: $1,805 · 2023: $1,501 · 2024: $1,645 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.69 |
| Education | $221.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.02 | 2019-2025 | Skyrizi, Rinvoq |
| Merz North America, INC. | $1,048.92 | 2019-2020 | |
| Janssen Biotech, INC. | $982.77 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $627.66 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $593.94 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $449.05 | 2019-2025 | |
| Incyte Corporation | $431.66 | 2021-2025 | Opzelura |
| Ucb, INC. | $393.64 | 2019-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $385.37 | 2022-2025 | Sotyktu |
| Pfizer INC. | $290.79 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $272.61 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $263.61 | 2019-2024 | Libtayo |
| Genzyme Corporation | $252.35 | 2019-2024 | |
| Leo Pharma INC. | $231.17 | 2019-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $201.30 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $194.21 | 2022-2023 | Vtama |
| Galderma Laboratories, L.P. | $180.19 | 2020-2024 | Oracea, Epsolay, Aklief |
| Celgene Corporation | $153.71 | 2019 | |
| Arcutis Biotherapeutics, INC. | $147.67 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Dermira, INC. | $65.00 | 2019-2020 | |
| Organon LLC | $23.86 | 2025 | Vtama |
| Biofrontera INC. | $15.59 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $14.90 | 2020 | |
| Genentech USA, INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Vicik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.